## Bortezomib Maintenance Therapy- 14 day

### INDICATIONS FOR USE:

<table>
<thead>
<tr>
<th>INDICATION</th>
<th>ICD10</th>
<th>Protocol Code</th>
<th>Reimbursement Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maintenance treatment for patients with high risk multiple myeloma</td>
<td>C90</td>
<td>00435a</td>
<td>Hospital</td>
</tr>
</tbody>
</table>

*If the reimbursement status is not defined the indication has yet to be assessed through the formal HSE reimbursement process*

### TREATMENT:

The starting dose of the drugs detailed below may be adjusted downward by the prescribing clinician, using their independent medical judgement, to consider each patient's individual clinical circumstances.

Bortezomib is administered once every 14 days for 2 years or until disease progression or unacceptable toxicity occurs.

<table>
<thead>
<tr>
<th>Day</th>
<th>Drug</th>
<th>Dose</th>
<th>Route</th>
<th>Cycle</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Bortezomib</td>
<td>1.3mg/m²</td>
<td>SC (abdomen or thigh)</td>
<td>Every 14 days</td>
</tr>
</tbody>
</table>

*a Note: In individual cases where approved by consultant, bortezomib may be administered as IV bolus over 3-5 seconds through a peripheral or central intravenous catheter followed by a flush with 0.9% NaCl. Note the concentration of bortezomib solution should be 1mg/ml when administered via the IV route*

*b The solution should be injected subcutaneously, at a 45-90° angle. Injection sites should be rotated for successive injections. If local injection site reactions occur, either a less concentrated solution may be administered sc or a switch to intravenous injection is recommended.*

Bortezomib is a proteasome inhibitor and is neurotoxic. Refer to **NCCP Guidance on the Safe Use of Neurotoxic drugs (including Vinca Alkaloids) in the treatment of cancer.**

### ELIGIBILITY:

- Indications as above
- ECOG 0-2

### EXCLUSIONS:

- Hypersensitivity to bortezomib, boron or any of the excipients
- Pregnancy

### PRESCRIPTIVE AUTHORITY:

The treatment plan must be initiated by a Consultant Haematologist working in the area of haematological malignancies.

### TESTS:

**Baseline tests:**

- FBC, renal, liver and bone profile.
- Blood pressure, blood glucose (patients on oral hypoglycaemics).
- Virology screen - Hepatitis B (HBsAg, HBCoreAb), C and HIV

**Hepatitis B Reactivation:** Patients should be tested for both HBsAg and HBCoreAb as per local policy. If either test is positive, such patients should be treated with Lamivudine 100 mg/day orally, for the entire duration of chemotherapy and for six months afterwards (Refer to local policy). Such patients should also be monitored with frequent liver function tests and hepatitis B
virus DNA at least every two months. If the hepatitis B virus DNA level rises during this monitoring, management should be reviewed with an appropriate specialist with experience managing hepatitis and consideration given to stopping chemotherapy.

Regular tests:
- FBC; monitor platelet count at a minimum of day 1 and day 8 each cycle,
- U&Es, LFTs, bone profile.
- Blood pressure, *blood glucose if being treated with oral hypoglycaemins. (* See Drug Interactions)

Disease monitoring:
Disease monitoring should be in line with the patient’s treatment plan and any other test/s as directed by the supervising Consultant.

DOSE MODIFICATIONS:
- Any dose modification should be discussed with a Consultant
- Bortezomib therapy should be withheld when the platelet count is < 25 x 10^9/L

Haematological:

Table 1: Dose modification of bortezomib based on haematological toxicity

<table>
<thead>
<tr>
<th>ANC (x 10^9/L)</th>
<th>Platelets (x 10^9/L)</th>
<th>Bortezomib Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 0.5 and ≥ 30</td>
<td>100% dose</td>
<td></td>
</tr>
<tr>
<td>&lt; 0.5 or &lt;30</td>
<td>Consider delay until recovery checking FBC weekly; reduce dose to 1.0 mg/m^2</td>
<td></td>
</tr>
<tr>
<td>Reoccurrence of &lt;0.5 or Reoccurrence of &lt;30</td>
<td>Consider delay until recovery checking FBC weekly; further reduce dose to 0.7 mg/m^2</td>
<td></td>
</tr>
</tbody>
</table>

Renal Impairment:

Table 2: Dose modification of bortezomib in renal impairment

Drug | Bortezomib |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>It is unknown if the pharmacokinetics of bortezomib are influenced in patients with severe renal impairment not undergoing dialysis (CrCL &lt; 20ml/min). Since dialysis may reduce bortezomib concentrations, it should be administered after the dialysis procedure.</td>
</tr>
</tbody>
</table>
Hepatic impairment:

Table 3: Dose modification of bortezomib in hepatic impairment

<table>
<thead>
<tr>
<th>Drug</th>
<th>Grade of Hepatic Impairment*</th>
<th>Bilirubin Level</th>
<th>SGOT (AST) levels</th>
<th>Modification of starting dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bortezomib</td>
<td>Mild</td>
<td>≤1 x ULN*</td>
<td>&gt; ULN</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>&gt;1 - 1.5 x ULN</td>
<td>Any</td>
<td></td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>Moderate</td>
<td>&gt;1.5 - 3 x ULN</td>
<td>Any</td>
<td>Reduce dose to 0.7mg/m² in the first treatment cycle. Consider dose escalation to 1mg/m² or further dose reduction to 0.5mg/m² in subsequent cycles based on patient tolerability.</td>
</tr>
<tr>
<td></td>
<td>Severe</td>
<td>&gt; 3 x ULN</td>
<td>Any</td>
<td></td>
</tr>
</tbody>
</table>

Based on NCI Organ Dysfunction Working Group classification for categorising hepatic impairment (mild, moderate, severe).

*ULN = Upper Limit Normal

Neuropathic pain and/or peripheral neuropathy:

Table 4: Recommended dose modifications for bortezomib-related neuropathy

<table>
<thead>
<tr>
<th>Severity of neuropathy</th>
<th>Dose Modification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 1 (asymptomatic; loss of deep tendon reflexes or paresthesia) with no pain or loss of function</td>
<td>None</td>
</tr>
<tr>
<td>Grade 1 with pain or Grade 2 (moderate symptoms; limiting instrumental Activities of Daily Living (ADL))</td>
<td>Reduce dose to 1 mg/m²</td>
</tr>
<tr>
<td>Grade 2 with pain or Grade 3 (severe symptoms; limiting self care ADL)</td>
<td>Withhold treatment until symptoms of toxicity have resolved. When toxicity resolves re-initiate treatment and reduce dose to 0.7mg/m² once every week</td>
</tr>
<tr>
<td>Grade 4 (life-threatening consequences; urgent intervention indicated) and/or severe autonomic neuropathy</td>
<td>Discontinue treatment</td>
</tr>
</tbody>
</table>

Grading based on NCI Common Toxicity Criteria CTCAE v 4.0
Dose reductions for other toxicities:

<table>
<thead>
<tr>
<th>Adverse reactions</th>
<th>Discontinue</th>
<th>Recommended dose modification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 3 Non-haematological toxicity</td>
<td>Withhold treatment until symptoms of the toxicity have resolved. Treatment may be re-initiated at a 25% reduced dose (1.3mg/m² reduced to 1.0mg/m²; 1.0mg/m² reduced to 0.7mg/m²). If the toxicity is not resolved or if it recurs at the lowest dose, discontinuation of bortezomib must be considered unless the benefit of treatment clearly outweighs the risk.</td>
<td></td>
</tr>
<tr>
<td>Skin rash</td>
<td>Withhold treatment and evaluate clinically. If allergic reaction do not resume treatment.</td>
<td></td>
</tr>
<tr>
<td>New or worsening pulmonary symptoms (e.g. cough, dyspnoea)</td>
<td>Withhold treatment. Prompt diagnostic evaluation required and benefit/risk ratio should be considered prior to continuing bortezomib therapy.</td>
<td></td>
</tr>
<tr>
<td>Posterior Reversible Encephalopathy Syndrome (PRES)</td>
<td>Discontinue bortezomib</td>
<td></td>
</tr>
</tbody>
</table>

SUPPORTIVE CARE:

EMETOGENIC POTENTIAL: Low (Refer to local policy).

PREMEDICATIONS: Not usually required. Ensure patient remains well hydrated during treatment.

OTHER SUPPORTIVE CARE:

- Bisphosphonates should be considered in all patients with myeloma related bone disease.
- Consider the use of a H₂ antagonist or proton pump inhibitor if appropriate in patients receiving dexamethasone therapy (Refer to local policy).
- Consider PJP prophylaxis (Refer to local policy).
- Consider low dose anti-viral prophylaxis (Refer to local policy).

ADVERSE EFFECTS / REGIMEN SPECIFIC COMPLICATIONS

The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details.

Bortezomib

- **Peripheral Neuropathy:** Patients with pre-existing severe neuropathy may be treated with bortezomib only after careful risk/benefit assessment.
- **Hypotension:** Treatment is commonly associated with orthostatic/postural hypotension. A minority of patients with orthostatic hypotension experienced syncopal events.
- **Hepatic Impairment:** Bortezomib is metabolised by liver enzymes. Bortezomib exposure is increased in patients with moderate or severe hepatic impairment; these patients should be treated with bortezomib at reduced doses and closely monitored for toxicities.
- **Haematological toxicity:** Gastrointestinal and intracerebral haemorrhage have been reported in association with bortezomib treatment. Therefore platelet counts should be monitored prior to each
The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician. and is subject to HSE’s terms of use available at http://www.hse.ie/eng/Disclaimer. This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoprotocols

dose of bortezomib and bortezomib should be withheld when the platelet count is < 25x 10^9 cells/L. Potential benefit of treatment should be carefully weighed against the risks, particularly in case of moderate to severe thrombocytopenia and risk factors for bleeding. Platelet transfusion should be considered when clinically appropriate.

- **Gastrointestinal toxicity:** Gastrointestinal toxicity, including nausea, diarrhoea, vomiting and constipation are very common with bortezomib treatment.
- **Seizures:** Seizures have been uncommonly reported in patients without previous history of seizures or epilepsy. Special care is required when treating patients with any risk factors for seizures.
- **Posterior Reversible Encephalopathy Syndrome (PRES):** In patients developing PRES, treatment with bortezomib should be discontinued.
- **Heart Failure:** Acute development or exacerbation of congestive heart failure, and/or new onset of decreased left ventricular ejection fraction has been reported during bortezomib treatment. Patients with risk factors for or existing heart disease should be closely monitored.

**DRUG INTERACTIONS:**
- Additive hypotensive effect with antihypertensives and bortezomib. Blood pressure should be monitored and ensure patient is well hydrated prior to bortezomib dose. Adjustment of antihypertensives may be required.
- During clinical trials, hypoglycemia was uncommonly reported and hyperglycemia commonly reported in diabetic patients receiving oral hypoglycemics. Patients on oral antidiabetic agents receiving bortezomib treatment may require close monitoring of their blood glucose levels and adjustment of the dose of their antidiabetics.
- Patients should be closely monitored when given bortezomib in combination with potent CYP3A4-inhibitors. Caution should be exercised when bortezomib is combined with CYP3A4- or CYP2C19 substrates.
- Current drug interaction databases should be consulted for more information.

**ATC CODE:**
Bortezomib - L01XX32

**REFERENCES:**
This is an unlicensed indication for the use of Bortezomib® in Ireland. Patient’s should be informed of this and consented to treatment in line with the hospital’s policy on the use of unlicensed medication and unlicensed or “off label” indications. Prescribers should be fully aware of their responsibility in communicating any relevant information to the patient and also ensuring that the unlicensed or “off label” indication has been acknowledged by the hospital’s Drugs and Therapeutics Committee, or equivalent, in line with hospital policy.

ODMS – Oncology Drug Management System
CDS – Community Drug Schemes (CDS) including the High Tech arrangements of the PCRS community drug schemes
Further details on the Cancer Drug Management Programme is available at; http://www.hse.ie/eng/services/list/5/cancer/profinfo/medonc/cdmp/